Approved for use in patients with rare blood disorder
Rare diseases drug company will move to new US site in 2015
Virgo Health helps create audio/visual installation
ARN-509 is in phase II development for castration resistant prostate cancer
New data from Cancer Research UK shines slight on 'quiet epidemic'
Decides on the Cambridge Biomedical Campus in UK
BMS and AbbVie present phase II results at European Haematology Association meeting
Phase II results showcased at European Hematology Association meeting
Will use MedImmune arm to develop treatments that target gastrointestinal hormones
The future of HTA harmonisation in EuropeThe variety and variability of European health technology assessment criteria have created a challenging environment for pharma and a need for much greater harmonisation
Carving an identity through customer-focused innovationBuilding pharma brands driven by customer-focused innovation will enable companies to differentiate their products in a crowded marketplace
Talking about a successful mergerHow communications can support effective mergers and acquisitions outcomes
Jakavi shows long-term survival benefit in myelofibrosisTrial demonstrates Novartis’ blood cancer drug cut risk of death by half over three years
Becomes first contraceptive of its kind to reach the UK market
BMS partners with Simcere to market arthritis drug Orencia SC in ChinaBuilds on existing cancer/ cholesterol alliance between pharma companies
Roche's Avastin gains Japanese approval for brain cancerMarks drug's first approval to treat newly diagnosed glioblastoma
US charity calls for release of diabetes drug dataAmerican Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer
FDA clears Amgen's Xgeva for rare bone conditionUS approval provides alternative to surgery for use in giant cell tumour of the bone
Partial victory for biotech sector after gene patent rulingUS Supreme Court decides genes can be patented, if synthetically produced
Former UK health secretary joins Bupa boardPatricia Hewitt will serve private health firm as non-executive director
Former Novartis president joins Qu BiologicsRobert Pelzer is appointed board member at immunotherapy specialists
ABPI appoints new director of commsCatherine Meaden was previously head of policy and public affairs at the body
Icon appoints Dr Neil McCullough to senior compliance roleHe joins the clinical research organisation from PPD
Summit appoints Pfizer/Bayer veteran as CMODavid Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile
STILL UK offers fork lift trucks, warehouse trucks, a national service network and financial service solutions for your intralogistics....